semaj83/ctmatch_classification huggingface dataset:
Patient description: A 56-year old Caucasian female complains of being markedly more sensitive to the cold than most people. She also gets tired easily, has decreased appetite, and has recently tried home remedies for her constipation. Physical examination reveals hyporeflexia with delayed relaxation of knee and ankle reflexes, and very dry skin. She moves and talks slowly.

Clinical trial eligibility criteria: eligible ages (years): 50.0-64.0,  Chronic Obstructive Pulmonary Disease for patients with COPD will be Signed informed consent prior to initiation of study-mandated vaccination Patients with spirometric data in the preceding 18 months confirming the diagnosis of COPD Patients meeting GOLD Classification of Stage C or Stage D COPD Patients 50 years old years old for Healthy participants will be Signed informed consent prior to initiation of study-mandated vaccination No active symptoms of lung disease FEV1/FVC in the normal range > 70% age predicted value  Severe allergy to eggs Severe reaction to past doses of influenza vaccine Guillian-Barre syndrome Currently recieving dialysis Current, active, treatment for cancer History of transplant (allograft) Dementia or Alzheimer's disease diagnosis Prior diagnosis of HIV or AIDS Moderate to severe pulmonary hypertension Serum AST/ALT > 3x the upper limit of normal
Patient description: A 56-year old Caucasian female complains of being markedly more sensitive to the cold than most people. She also gets tired easily, has decreased appetite, and has recently tried home remedies for her constipation. Physical examination reveals hyporeflexia with delayed relaxation of knee and ankle reflexes, and very dry skin. She moves and talks slowly.

Clinical trial eligibility criteria: eligible ages (years): 17.0-70.0,  Cough chronic cough group cough lasting ≥ 8 weeks,characterized by irritating dry cough sensitive to fumes，dust,the odorous and cold air with normal chest x-rays. 4.17-70 years old without smoking history. healty controls group: 1.17-70 years old. 2.without smoking hitory or stop smoking for more than 2 years. 3.without chronic cough. 4.without chronic respiratory diseases. 5.without chronic heart, liver, kidney,and autoimmune disease. 6.with normal chest x-rays. 7.with normal pulmonary ventilation function,and histamine challenge test showed negative result  chronic cough group and healty controls group with respiratory tract infection within 8 weeks with chronic respiratory diseases or severe heart, liver, kidney,and autoimmune disease using Angiotensin-Converting Enzyme Inhibitors(ACEI),bronchodilators,glucocorticosteroid,antihistaminics within one week women during pregnancy or lactation patients with malignant tumours
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  HIV Infections   Co-existing Condition Patients with the following are excluded Neuropsychological (NP) impairments more severe than described in the Criteria Evidence of nervous system dysfunction being caused by factors other than HIV infection, including history of head trauma, multiple sclerosis, epilepsy, or presence of concurrent central nervous system (CNS) infections or neoplasms, e.g., toxoplasmosis, primary or metastatic CNS lymphoma, progressive multifocal leukoencephalopathy, cryptococcal or other fungal meningitis, and CNS tuberculous infections Lymphoma or other tumor requiring cytotoxic chemotherapy Concurrent Medication Excluded Other antiretroviral agents Patients with the following are excluded AIDS or advanced ARC
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  West Nile Virus In order to participate in this clinical trial, all subjects (or legal representative) must provide written informed consent. Only patients meeting entry will be enrolled. Eligible subjects must fall into one of two categories A. Hospitalized patients greater than or equal to 18 years of age with encephalitis and/or myelitis as defined below New neurologic abnormality Asymmetric extremity weakness without sensory abnormality; or Other neurologic abnormality (including altered level of consciousness, dysarthria and dysphagia) plus fever (subjective or objective) within the previous 4 days AND CSF examination within the previous 96 hours showing Absence of organism on gram or fungal stain White blood cell count greater than or equal to 4 per mm(3) corrected for significant red blood cell contamination Ratio of CSF: plasma glucose of greater than or equal to 40% (CSF glucose/plasma glucose greater than or equal to 0.4)  Unable to obtain valid informed consent History of intolerance (including anaphylaxis) to IVIg or related compounds Known history of IgA deficiency Known history of hypersensitivity to maltose History of (or at time of study entry) hyperviscosity syndrome including but not limited to Waldenstrom's macroglobulinemia Multiple myeloma Total white blood cell count greater than 80,000/mm(3) Hematocrit greater than 55% Platelet count greater than 700,000/mm(3)
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  HIV Infections HIV uninfected At low risk for HIV infection Willing to receive HIV test results Good general health Acceptable methods of contraception for females of reproductive potential Hepatitis B surface antigen negative Anti-hepatitis C virus antibody (anti-HCV) negative or negative HCV PCR if anti-HCV is positive Meets educational requirements of the study  HIV vaccines or placebos in prior HIV vaccine trial Immunosuppressive medications within 168 days prior to first study vaccine administration Blood products within 120 days prior to first study vaccine administration Immunoglobulin within 60 days prior to first study vaccine administration Live attenuated vaccines within 30 days prior to first study vaccine administration Investigational research agents within 30 days prior to first study vaccine administration Subunit or killed vaccines within 14 days prior to first study vaccine administration Allergy treatment with antigen injections within 30 days prior to first vaccine administration Current tuberculosis prophylaxis or therapy Serious adverse reaction to a vaccine. A person who had an adverse reaction to pertussis vaccine as a child is not excluded
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 17.0-65.0,  Spinal Cord Injuries Injured subjects Complete or incomplete acute SCI between C0 and T11 Admitted within 48 hours of injury Undergoing spinal decompressive surgery Undergoing lumbar puncture for spinal anesthetic or myelography Neurologically intact  Pre-existing neurodegenerative disorder Associated head or spine injury
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Pneumococcal Meningitis Adults (> 18 yr) with suspicion of pneumococcal meningitis requiring intensive care unit  Allergy to one of the antibiotics used in the study
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  HIV Infections Lymphoma, AIDS-Related Adult (18 years old or older) HIV-infected patient HIV infected by OraQuick rapid test using saliva, venipuncture whole blood, or fingerstick whole blood; or by reactive ELISA and Western Blot as determined by an outside CLIA-approved laboratory facility or by NIH Clinical Pathology Laboratory or SAIC-Frederick Inc Monitoring Laboratory. HIV infection as determined by an outside CLIA-approved laboratory facility will be verified by a standard HIV-1 ELISA with Western Blot confirmation prior to brain biopsy Evidence of contrast-enhancing focal brain lesion(s) as seen on MRI or CT Willingness to give informed consent and provided by Durable Power of Attorney. In the event that no Durable Power of Attorney has been designated and the patient is unable to do so, the NIH Ethics Committee will be consulted. All patients must designate a Durable Power of Attorney in order to participate in the study Willingness to undergo the procedures involved in the diagnostic evaluation: lumbar puncture, FDG-PET scan, 201Tl-SPECT scan, and brain biopsy Permit the storage of blood, CSF, and tissue samples for future research use Willingness to undergo HLA testing  Previous PCNSL History of prior malignancy other than PCNSL unless in remission for 1 year or longer; non-melanoma skin cancer and Kaposi's sarcoma excepted History of previous diagnosis of toxoplasmic encephalitis or other CNS infection causing focal contrast-enhancing brain lesions Pregnancy or currently breast feeding Have any other condition that the research team considers a contraindication to participating in the study, e.g. severe cardiac, renal, or pulmonary dysfunction Weight greater than 400 lb for PET and 500 lb for SPECT (limit of the gantry)
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 0.0-14.0,  Pneumococcal Meningitis All children from 0 up to 14 years with diagnosis of confirmed or probable pneumococcal meningitis or with diagnosis of suspected bacterial meningitis without bacterial or viral isolation will be included into the study
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 18.0-64.0,  Back Pain Need a lumbar or cervical myelogram as part of routine care  Not needing a myelogram in the cervical or lumbar spine
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 8.0-18.0,  Migrainous Headache Males or Females age 8-18 years Girls 11 years or older must have a negative urine/serum pregnancy test Diagnosis of pediatric migrainous headache. The for pediatric migraine headache based on the most recent ICHD are listed below. The requirement of 5 attacks (A) will not be required for this study, this making the diagnosis migrainous headache. As described elsewhere in the protocol, this change is required to make the study applicable to ED patients who require treatment before five attacks have occurred  Evidence that headache is due to a secondary underlying disorder based on history or physical examination Pregnant or lactating females Any investigational drug use within 30 days Known to have a contraindication to metoclopramide or valproic acid such as pregnancy, liver disease, hematologic disease, or metabolic disease Have used metoclopramide (or other antidopaminergic medications) or valproic acid within two days of presentation Severe developmental disorders or mental retardation if insufficient information can be obtained to make a clear diagnosis of migraine or judge headache severity If patients re-present to the ED, they can not be re-enrolled
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Minor Head Injury Traumatic Brain Injury head injury, nausea, vomiting  no head injury
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cardiac Arrest Arrhythmia Cardiac Arrest Patients 18 years and older with cardiac arrest in the hospital and successfully resuscitated, or with cardiac arrest out of the hospital and successfully resuscitated ICD patients Patients 18 years and older Who are undergoing elective procedure in the electrophysiology laboratory for placement of a cardiac defibrillator and who will most likely undergo induction of ventricular arrhythmia as part of the procedure  Cardiac Arrest Cardiac arrest and a known pre-existing cerebral pathology such as brain tumor, cerebral hemorrhage, encephalitis or immediately post-op neurosurgery CNS infection Skull defects and scalp diseases that are not amenable to standard EEG testing ICD patients Known pre-existing cerebral pathology such as brain tumor, cerebral hemorrhage, encephalitis or immediately post-op neurosurgery CNS infection Skull defects and scalp diseases that are not amenable to standard EEG testing
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 20.0-65.0,  Post-Traumatic Stress Disorder Patients who are primarily diagnosed with PTSD (Posttraumatic Stress Disorder: 309.81) using DSM-IV-TR criteria. The CAPS-DX (Clinician-Administered PTSD Scale-DX) and M.I.N.I. (The Mini International Neuropsychiatric Interview, Japanese version 5.0.0. [2003]) will be used for diagnosis Pathologic condition: Patients who experienced a motor vehicle accident (MVA) with severe or potential severe physical injury more than 3 months ago but less than 12 months ago Patients aged 20 and <65 at the time of signing the Informed consent Male and female patients Inpatient/outpatient status: Both are permitted Patients who are able to give written informed consent in person (i.e., patients who are capable of giving written informed consent on their own) Patients whose combined score of the CAPS-SX standard B, C, and D is over 50  Patients primarily diagnosed with a DSM-IV-TR Axis I disorder other than PTSD (e.g. major depressive disorder, dysthymic disorder, specific phobia [simple phobia], obsessive-compulsive disorder, panic disorder, etc.) within 6 months of week -4 (start of baseline phase) Patients presenting with a current major depressive episode that preceded the diagnosis of PTSD Patients receiving disability payments due to PTSD or other psychiatric diseases Patients currently engaged in compensation litigation whereby personal gain would be achieved from prolonged symptoms of PTSD or any other psychiatric disorders Patients who meet the DSM-IV-TR for substance abuse or dependence (alcohol or drugs) within 6 months of Week -4 (start of baseline phase) Patients with history of a suicide attempt within 6 months before Week -4 (start of baseline phase), or have, in the opinion of the investigator, "C. high risk of suicide" according to the MINI at Week -4 Patients who are pregnant, lactating or of childbearing potential and are likely to become pregnant Patients receiving electro-convulsive therapy (ECT) prior to Week -4 (start of baseline phase) Patients receiving another investigational product within 12 weeks before Week -4 (start of baseline phase) Patients with a history or complication of manic psychosis
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Chiari Malformation Type I Age >18 years Clinical Diagnosis of Chiari Type I Malformation Radiogrpahic evidence of downward tonsillar herniation (displacement of the lower part of the cerebellum below the level of the skull) Signed Written Informed Consent  Presence of Hydrocephalus or previous CSF diversion procedure, such as shunt Prior operation on the posterior cranial fossa Inability to understand the informed consent or unwillingness to participate in the study Inability to return for follow-up evaluation 3 months after the surgery Evidence of spinal dysraphism Allergy or history of allergic reaction to Duragen, Duraguard, or their components Pregnancy as documented by a urine or blood test
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Spinal Procedure Requiring Dura Incision Patients who are scheduled for an elective spinal procedure that requires a dural incision will be considered for study participation Patient requires a procedure that involving surgical wound classification Class 1/Clean (per CDC criteria) Presence of a non-watertight dural closure, either spontaneously or upon Valsala maneuver at 20-25 cm H20 for 5-10 seconds  Active spinal and/or systemic infection Patient requires additional spinal surgery within the study time period Patient has had a previous spinal surgery involving dural exposure and/or entry at the same level(s) as the study procedure Patient has a pre-existing external lumbar CSF drain or internal CSF shunt Patient is participating in a clinical trial of another investigational device or drug Patient with creatinine > 2.0 mg/dL Patient with total bilirubin > 2.5 mg/dL Pregnant or breast-feeding females or females who wish to become pregnant during the length of study participation Patient has been treated with chronic steroid therapy (>4 weeks) unless discontinued more than 6 weeks prior to surgery Patient has documented history or significant coagulopathy with a PTT >35 sec, PT/INR >1.2, receiving asprin, or at the time of surgery
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 0.167-15.0,  Bacterial Meningitis All children aged ≥ 2 months, admitted to Queen Elizabeth Hospital, Blantyre, Malawi, with possible or confirmed acute bacterial meningitis  Age less than two months Trauma Relevant underlying illness such as intracranial shunt, previous neurological disease (cerebral palsy, Down's syndrome) Previous permanent hearing loss (not conductive hearing loss) if known Immunosuppression except HIV infection
Patient description: A 44-year-old man was recently in an automobile accident where he sustained a skull fracture. In the emergency room, he noted clear fluid dripping from his nose. The following day he started complaining of severe headache and fever. Nuchal rigidity was found on physical examination.

Clinical trial eligibility criteria: eligible ages (years): 18.0-45.0,  Familial Mediterranean Fever Fulfilling the Tel Hashomer for the diagnosis of FMF [5] Suffering from episodes of exertional leg pain and or exertional ankle edema 18-45 years old On a stable (≥ 2 weeks) dose of oral colchicine therapy Non-smokers  with known peripheral vascular disease (PVD) and/or multiple risk factors for PVD (such as diabetes, hypertension, hyperlipidemia) Suffering from muscular or neurological diseases not related to FMF With elevated serum creatinine / liver enzymes/ creatine phosphokinase (CPK) levels Suffering from claustrophobia, or with metal fragments in body tissue, or with other contraindications for MRI